Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ZyVersa Therapeutics, Inc. - Common Stock (NQ: ZVSA ) 2.300 +0.070 (+3.14%) Streaming Delayed Price Updated: 3:59 PM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 20,712 Open 2.230 Bid (Size) 2.210 (1) Ask (Size) 2.470 (10) Prev. Close 2.230 Today's Range 2.230 - 2.340 52wk Range 2.080 - 62.30 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket September 17, 2024 Via Benzinga ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024 August 09, 2024 ZVSA stock results show that ZyVersa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace Performance YTD -73.86% -73.86% 1 Month -21.23% -21.23% 3 Month -36.46% -36.46% 6 Month -69.33% -69.33% 1 Year -95.25% -95.25% More News Read More ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update August 09, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation August 07, 2024 From ZyVersa Therapeutics Via GlobeNewswire Peering Into ZyVersa Therapeutics's Recent Short Interest May 21, 2024 Via Benzinga ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults July 29, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100 July 25, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model July 18, 2024 From ZyVersa Therapeutics Via GlobeNewswire SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL July 11, 2024 Via AB Newswire ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024 July 09, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024 May 15, 2024 Via InvestorPlace ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update May 15, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention May 14, 2024 From ZyVersa Therapeutics Via GlobeNewswire Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 29, 2024 Via Benzinga What's Going On With ZyVersa Stock? April 29, 2024 Via Benzinga ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease April 29, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes April 04, 2024 From ZyVersa Therapeutics Via GlobeNewswire Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session April 26, 2024 Via Benzinga ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update March 25, 2024 From ZyVersa Therapeutics Via GlobeNewswire Benzinga's 2024 Virtual Healthcare: What's Next In Health? March 19, 2024 Via Benzinga ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease March 18, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024 March 14, 2024 From ZyVersa Therapeutics Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session March 07, 2024 Via Benzinga ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity February 29, 2024 From ZyVersa Therapeutics Via GlobeNewswire ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications February 28, 2024 From ZyVersa Therapeutics Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
